Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR

Launched by JORDAN COLLABORATING CARDIOLOGY GROUP · Aug 23, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR," is looking to understand how common a condition called ATTR cardiac amyloidosis is among older patients who have severe aortic stenosis and are scheduled to undergo a heart procedure called TAVR. Aortic stenosis is a narrowing of the heart's aortic valve, which can cause serious health issues. Researchers believe that there might be a link between this heart condition and the buildup of amyloid proteins, which can damage the heart.

To be eligible for this study, participants must be at least 65 years old, diagnosed with severe aortic stenosis, and undergoing the TAVR procedure. They will also need to have a specific positive test result related to their heart condition. Unfortunately, patients with another type of amyloidosis called AL amyloidosis will not be able to participate. Those who join the trial can expect to undergo evaluations to check for the presence of ATTR cardiac amyloidosis, helping to improve understanding of this condition in elderly patients. This research is important as it could lead to better care and treatment options for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥65 years
• • Severe aortic stenosis
• • Patient underwent TAVR procedure
• • Positive pyruvate PO4 scan
• Exclusion Criteria:
• • Diagnosis of AL amyloidosis base on free light chain assay, serum and urine immune electrophoresis.